TREATMENT WITH ANTISENSE OLIGODEOXYNUCLEOTIDE TO THE OPIOID DELTA-RECEPTOR SELECTIVELY INHIBITS DELTA(2)-AGONIST ANTINOCICEPTION

USING approaches emphasizing differential antagonism of receptor selective agonists and cross-tolerance paradigms, evidence in vivo has suggested the existence of subtypes of opioid delta receptors, which have been termed delta(1), and delta(2). Recent work has elucidated the structure of an opioid delta receptor. The present investigation attempted to continue to test the hypothesis of subtypes of delta receptors and to correlate the cloned delta receptor with the existing pharmacological classification. Synthetic oligodeoxynucleotides (oligos) complementary to the 5' end of the cloned delta receptor coding region (antisense) or its corresponding sequence (sense) were given by intracerebroventricular (i.c.v.) administration to mice, twice-daily for 3 days and antinociceptive responses to selective agonists at putative delta(1) and delta(2) receptors were subsequently determined. Treatment with antisense, but not sense, oligo significantly inhibited the response to [D-Ala(2),Glu(4)]deltorphin (delta(2) agonist), but not to [D-Pen(2),D-Pen(5)]enkephalin (DPDPE, delta(1) agonist). Further, subsequent administration of DPDPE elicited a full antinociceptive response in the same antisense oligo treated mice which did not show a significant response to [D-Ala(2),Glu(4)]deltorphin while antisense oligo treated mice which responded to DPDPE did not show antinociception when tested subsequently with [D-Ala(2), Glu(4)]deltorphin. The data suggest that the cloned delta receptor corresponds to that pharmacologically classified as delta(2) and continue to support the concept of subtypes of opioid delta receptors.